|Bid||0.0000 x 2900|
|Ask||0.0000 x 900|
|Day's range||3.4000 - 3.6375|
|52-week range||2.7800 - 8.5800|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Avis Budget, Q2, bluebird bio, Equitrans Midstream, and Financial Services. Avis Budget Group (NASDAQ:CAR) shares gained more than 2% yesterday after Deutsche Bank upgraded the company to Buy from Hold and raised its price target to $263.00 from $239.00, as InvestingPro reported in real time.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
With the stock down 52% in the last three months, Bluebird Bio (NASDAQ: BLUE) shareholders are bound to be feeling pretty antsy. Between the company's weak cash position, missed deadline for a drug candidate submission to regulators, and 30% cut in its workforce a year ago, there hasn't been much to celebrate lately. First, while it did miss its goal of submitting its approval packet for a therapy called lovo-cel to the Food and Drug Administration (FDA) in the first quarter, it says that once the FDA gets back to it in a few weeks, it'll do so.
The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Whereas CRISPR's shares fell by 31%, Bluebird's are down by 33%. CRISPR Therapeutics is on track to have a transformative 2023, but its biggest risk is that regulators will stymie its efforts to commercialize its gene therapy candidate exa-cel, which aims to treat beta thalassemia and sickle cell disease.
Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.
Last year was an important one for Bluebird Bio (NASDAQ: BLUE) as the biotech company earned two key regulatory approvals in the U.S. Despite these wins, the market has hardly rewarded the gene-editing specialist; its shares are down 39% in the past year, and Bluebird's market capitalization is currently just $323 million. The company's newly approved therapies are Zynteglo, which targets transfusion-dependent beta-thalassemia (TDT, a rare blood disorder), and Skysona, a medicine for cerebral adrenoleukodystrophy (CALD, a progressive, pediatric, and fatal neurodegenerative disease). The issue here is whether third-party payers will agree to cover these medicines.
Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.
Every investor in bluebird bio, Inc. ( NASDAQ:BLUE ) should be aware of the most powerful shareholder groups. And the...
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Just as the Nasdaq Composite (NASDAQINDEX: ^IXIC) led markets lower in 2022, the index is working hard to lead a rebound early in 2023. After being the only one of the three major U.S. stock market indexes to finish higher on Tuesday, the Nasdaq once again looked good early Wednesday morning, with futures on the index rising nearly half a percent. One winner leading the Nasdaq higher Wednesday morning was vaccine stock Moderna (NASDAQ: MRNA), which announced positive news that showed investors the company is more than just a one-trick pony.
After all, many currently well-established companies were once small- or mid-cap stocks. Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year.
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.
Investors need to pay close attention to bluebird bio (BLUE) stock based on the movements in the options market lately.
Bluebird Bio (NASDAQ: BLUE) stock got off to a roaring start on Monday, trouncing the S&P 500 index with a nearly 8% gain. The market was cheered by a clinical update and the potential for a new regulatory application in the near future. On Saturday at a healthcare conference, Bluebird presented recent data on its gene therapies for beta-thalassemia and sickle cell disease (SCD).
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Investing in biotech companies, especially relatively small ones, can be a double-edged sword. With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Right now, CRISPR Therapeutics is a clinical-stage biotech.
Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gene editing refers to techniques that allow researchers to modify the DNA of various organisms. Given that it offers the potential to help discover innovative therapies, it isn't surprising that more and more drugmakers are turning to the technology. Two prominent biotechs that focus on gene editing are CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE).